![]() |
The Difference in Guanfacine Formulations for ADHD...
December 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Attention-deficit/hyperactivity disorder (ADHD) is the most common pediatric psychiatric disorder, and it affects the education, social interactions, and over-all wellbeing of both children and adolescents.1 Symptoms of ADHD can persist into adulthood, and those with this disorder are more likely to suffer from other mental health co-morbidities.2 According to guidelines… |
![]() |
Using Bacteriophage Enzymes to Stay One Step Ahead of M...
December 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Copy Editor [Content-Focused] – It’s difficult to have a discussion about antibiotics without mentioning the developing crisis of antibiotic-resistance. Pathogens like MRSA (methicillin-resistant Staphylococcus aureus) have become a part of the general public’s consciousness – a household name and a community-acquired “superbug.” With the last new class of antibiotics developed in the… |
![]() |
Recombinant Factor IX (Alprolix) Brings Hope for Hemoph...
December 1, 2014 - Featured , In the News / Politics By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently… |
![]() |
Reservoir of Migraine Therapies Includes Analgesics, AE...
September 1, 2014 - Clinical , Featured By Davidta Brown, Senior Staff Editor – The pain, nausea, and light or sound sensitivity that comprise a migraine attack afflict more than 10% of individuals around the world, easily making migraines one of the most globally debilitating diseases of the present day.1 According to the International Headache Society (IHS), migraines are defined by both… |
![]() |
Drug Shortages: Effects & Costs in the United Stat...
August 1, 2014 - Featured , Professional Advice / Opinions By: Valentina DiGangi,PharmD Candidate c/o 2017, Brandon Hu, PharmD Candidate c/o 2018, Sang Hyo Kim, Staff Editor, Samantha Lau, PharmD Candidate c/o 2018, and Seowoo Yoon, PharmD Candidate c/o 2018 – What does a clinician do when there is limited access to a particular drug, such as morphine? Should they treat a patient who is… |
![]() |
Tailored Tablets...
August 1, 2014 - Featured , In the News / Politics By: Azia Tariq, Staff Editor – Truly personalized medication is the goal of researchers in the pharmaceutical and biotechnological industries. For example, when a patient requires a precise dose that is not manufactured as a tablet, the tablet will be broken up in order to deliver the dose as close as possible. Not only is… |
![]() |
Antipsychotic Use in the Elderly with Dementia...
July 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – The overuse of antipsychotics in the nursing home population for off-label indications continues to impact patient safety. In 2005, the FDA issued a black box warning that stated, “The treatment of behavioral disorders in elderly patients with dementia with atypical antipsychotic medications is associated with increased mortality.” The evidence… |
![]() |
The Dangers of Intrathecal Baclofen...
June 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – Intrathecal baclofen (ITB) is indicated for the treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, spinal ischemia or tumor, transverse myelitis, cervical spondylosis, cerebral palsy, and degenerative myelopathy.1 Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal cord level by decreasing excitatory neurotransmitter release from… |
![]() |
The Surgeon General’s 2014 Report on Smoking...
April 1, 2014 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Since the first release of the Surgeon General’s Report on smoking 50 years ago, it has become clear that smoking results in premature death and a myriad of diseases, affecting almost every organ system. Public health initiatives to increase awareness, prevent initiation, and promote smoking cessation have been marginally… |
![]() |
Tasimelteon (Hetlioz®): First FDA Approved Pharmacolo...
April 1, 2014 - Featured , In the News / Politics By: Beatrisa Popovitz, Senior Staff Editor – On January 31st 2014, the FDA announced the release of a revolutionary new drug, tasimelteon (Hetlioz®). Tasimeleton is the first developed treatment of non-24-hour sleep-wake cycle syndrome in blind individuals.1 Formulated by Vanda Pharmaceuticals Inc., this melatonin receptor agonist works by binding to and activating the MT1 and… |
![]() |
New Legislation Redefines Oversight for Compounding Pha...
April 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Senior Staff Editor – As the world of healthcare and its provision evolves, laws which organize and oversee the ways that patients receive health services must develop at the same pace. Last November, a new bill establishing clearer protocol for the compounding and tracking of medications became national law. The Drug Quality… |
![]() |
A Brave New World for Lipid Management...
March 1, 2014 - Featured , In the News / Politics By: Amrita Singh, PharmD Candidate c/o 2015 – Last November, the American College of Cardiology and the American Heart Association released new lipid guidelines, which will transform the way we manage our patients with hyperlipidemia. Earlier, lipid management was based on the ATP-III guidelines, which emphasized the use of several lipid-lowering medications to reach target… |
![]() |
To Defend the People...
February 1, 2014 - Featured , Professional Advice / Opinions By: Davidta Brown, Senior Staff Editor – As the world’s largest market for pharmaceuticals, the United States receives many medications manufactured abroad.1 Patients, physicians, and pharmacists defer the responsibility of ensuring the quality of these imported drugs to the FDA, but it only takes one report of deceit in the pharmaceutical industry for this trust… |
![]() |
Possible Inhaled Option for Diabetics...
December 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – Near the end of December, the pharmaceutical company, MannKind Corp, will submit their clinical data to the U.S Food and Drug Administration for the approval of an inhaled dosage form of insulin, Afrezza®.1 Administered with the Dreamboat inhaler, this inhaled dosage form delivers insulin packaged into single dose… |
![]() |
Does Moxifloxacin Increase the Risk of Dysglycemia?...
November 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2014, AMSCOP at LIU – The antibiotic class known as the fluoroquinolones is widely used in both outpatient and inpatient settings. They provide bactericidal effects by inhibiting DNA gyrase and topoisomerase IV enzymes in bacteria. The systemic agents that are most commonly used in clinical practice include ciprofloxacin, levofloxacin,… |
![]() |
New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to… |
![]() |
Ketoconazole No More...
October 1, 2013 - Featured , In the News / Politics By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms… |
![]() |
Hope For Children with Acute Lymphoblastic Leukemia...
October 1, 2013 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Emily Whitehead, a 7-year-old girl who fought off relapsing acute lymphoblastic leukemia (ALL), has captured the hearts and prayers of the masses. Her story is an inspiration to those battling any disease with a poor prognosis and particularly holds promise for the 15% of children with ALL resistant to… |
![]() |
Olmesartan Medoxomil Label Revision...
September 1, 2013 - In the News / Politics By: David Ong, PharmD Candidate c/o 2014 – Manipulating the renin-angiotensin system is one of the many ways drugs are used to treat hypertension. By blocking key steps in the renin-angiotensin cascade, blood pressure decrease may be achieved. Angiotensin II receptor blockers (ARBs) represent one of the drug classes that utilize the aforementioned mechanism. ARBs… |
![]() |
HIV Test: Making a Difference...
September 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – On June 27, 2013, the Centers for Disease Control and Prevention (CDC), AIDS.gov, and other national and local entities organized the 19th annual National HIV Testing Day. On this day, the theme of “Take the Test, Take Control” was employed to spread awareness of testing and prevention methods… |
![]() |
iPod, iPad, iPhone… iLimb...
August 1, 2013 - Featured , In the News / Politics By: Sang Hyo Kim, Staff Editor – There is a new invention called “i-limb ultra revolution,” which allows amputees to control their prosthetic hands with an Apple® app called “Bioism.” Designed by Touch Bionics in the United Kingdom, the new prosthetic hand has five individually powered fingers, including a powered rotating thumb and an auto-grasp… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
FDA Takes Major Strides Towards Opioid Abuse Prevention...
June 1, 2013 - Featured , In the News / Politics By: Ada Seldin PharmD Candidate c/o 2015 – On April 16th, 2013, the FDA approved the labeling change for the reformulated OxyContin® (oxycodone hydrochloride controlled-release) tablets, made by Pharma L.P. This change reflects the abuse-deterrent properties of the reformulated OxyContin®, which were not present in the original formulation approved by the FDA in 1995. OxyContin®… |
![]() |
Helping Solve the Cruel Mystery...
June 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Senior Staff Editor – Lupus is highly unpredictable and occurs without warning; there is no known cause and no known cure. It affects over 1.5 million Americans, 90% of whom are women between the ages of 15 – 44.1 No two cases of lupus are alike, making it a very difficult disease… |
![]() |
Can a Pharmacist Prevent the Next Pileup?...
May 1, 2013 - Clinical By: Moisey Rafailov, PharmD Candidate c/o 2015 – It was early in the morning on New York’s Route 684 when a car hit a tractor-trailer and continued driving without regard. Imagine that, when later stopped by a police officer, the driver said that the accident was her pharmacist’s fault. What if I were to tell… |
![]() |
Plan B® Pill Now Available Without Prescription to Wom...
May 1, 2013 - Featured , In the News / Politics By: Bansri Patel – As of May 1st 2013, Plan B®, the brand name emergency contraception pill will now be available to women aged fifteen and older. It will also be sold in the drug store aisles, as opposed to its current location behind the pharmacy counter. When levonorgestrel (Plan B®) first entered the market,… |
![]() |
Merck Settles Lawsuits Over Vytorin...
April 1, 2013 - In the News / Politics By: Tasnima Nabi, Staff Editor – Merck & Co. will pay $688 million to settle two lawsuits filed in December 2008 over their patent-protected statin, Vytorin®. The suits state that Merck and Schering-Plough delayed releasing the results of their ENHANCE study to avoid a decrease in revenue.1 Vytorin® is a combination drug of simvastatin and… |
![]() |
Liraglutide (Victoza®) for Type 2 Diabetes Mellitus...
February 1, 2013 - Clinical , Featured By: Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s… |
![]() |
Emerging Pathways For Treating Hepatitis C Virus...
February 1, 2013 - Clinical , Featured By: Maria Sorbera, PharmD Candidate c/o 2013, AMSCOP, LIU – Hepatitis C is the leading cause of chronic liver disease and cirrhosis, presenting a global health challenge. Approximately 170 million people worldwide, 3% of the population, are infected with the Hepatitis C Virus (HCV), roughly 3.2 million of whom reside in the United States. The… |
![]() |
Varizig® for Chickenpox Symptoms...
January 1, 2013 - In the News / Politics By: Steve Soman, Co-Editor-in-Chief – Varicella Zoster Immune Globulin (Varizig®) was approved by the FDA on December 21st of 2012. The Canadian pharmaceutical company Cangene Corporation, which is owned in-part by Apotex Inc., markets the new product. The drug was approved by the Food and Drug Administration (FDA) to reduce “the severity of chicken pox… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Low-dose SSRIs for the Overly Sensitive Esophagus...
November 1, 2012 - Clinical , Featured By Sunhae Chang, PharmD Candidate c/o 2013 – When patients complain of heartburn, the blame usually shifts to gastroesophageal reflux disease (GERD). Therefore, patients receive the “standard therapies for GERD”: antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), or prokinetics.1,2 Luckily, most patients respond well to these agents.1,2 Unfortunately, the not-as-lucky ones, despite PPI… |
![]() |
Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality. The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.… |
![]() |
Quick Update: Triptan Pharmacology...
August 1, 2012 - Clinical By: Neal Shah, Co-Editor-In-Chief – Migraines can be “classic” or “common.” While all migraines feature unilateral, pulsating headaches, classic migraines feature an “aura” upon onset (whereas common migraines do not). Pharmacologic treatment of migraines generally includes serotonin agonists (triptans).1 Triptans are selective agonists of the 5-hydroxytryptamine 1B and 1D (5HT1B/1D) subtypes. By activating these receptors,… |
![]() |
Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug. First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing… |
![]() |
Rho Chi Post Interview with Dean Mangione...
May 1, 2012 - Featured , Professional Advice / Opinions By: Mohamed Dungersi & Mahdieh Danesh Yazdi, Associate Student Editors – Each month, the editors at the Rho Chi Post have the opportunity to interview one or more of our faculty members. This month, we had the tremendous opportunity to interview the dean of St. John’s University College of Pharmacy and Allied Health Professions, Dean… |
![]() |
Sativex®: A Realistic Option for Advanced Cancer Pain?...
April 1, 2012 - Clinical , Featured , In the News / Politics By: Kathlynn Ferrer, Pharm.D. Candidate c/o 2013 – Nabiximols (Sativex®) is a buccal spray that has been approved for use in the UK, Spain, Germany, Denmark, New Zealand, and Canada. The active ingredients in this product are Tetrahydrocannabinol and Cannabidiol, two kinds of cannabinoids1. Cannabinoids are chemical compounds that stimulate cannabinoid receptors and are the… |
![]() |
HMG-CoA Reductase Inhibitors And Memory Loss...
April 1, 2012 - Clinical , Featured By: Yufan (Frank) Liu, Pharm.D. Candidate c/o 2013 – Results of numerous epidemiological studies have indicated that having high serum cholesterol can lead to coronary heart disease (CHD). 1 More specifically having high LDL cholesterol puts patients at risk for angina and heart attack.2 To reduce this risk HMG-CoA reductase inhibitors, also known as statins,… |
![]() |
The Diagnosis and Management of Bipolar Disorder in Chi...
March 1, 2012 - Clinical By: Marie Huang – The amphitheater at Nassau University Medical Center fills up slowly as Dr. Alan Jay Cohen, a psychiatrist from Oakland, California, makes his way up to the podium to lead a talk about bipolar disorder, specifically differentiating between its presentations in adults versus in developing children. Among nonprofessionals, bipolar disorder is simply… |
![]() |
Medco & Express Scripts Merger...
February 1, 2012 - In the News / Politics By: Alisha Kumar, PharmD Candidate c/o 2012 – Express Scripts proposed a $29 billion acquisition of Medco Health back in July 2011, and Medco’s shareholders almost unanimously accepted the offer. According to Medco’s press release, the plan was approved by a margin of 99% to 1%, with approximately 72% of its shareholders voting. The two… |
![]() |
Bydureon®: A Weekly Injection for Type 2 Diabetes Mell...
February 1, 2012 - Clinical , Featured , In the News / Politics By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise. Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide). It is the first once-a-week medication for T2DM in the market.… |
![]() |
Hope on the Horizon: Chikungunya Vaccine Trial Begins!...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Ebey P. Soman – Since its discovery in Tanganyika (modern day Mozambique and Tanzania in Africa) in 1952, Chikungunya virus outbreaks have been documented in Africa, South Asia, and Southeast Asia. Due to recent globalization and increased travel, infection has also spread outside of tropical regions and even into western nations (such as the… |
![]() |
Differences Between Antagonists and Inverse Agonists...
December 1, 2011 - Clinical By: Neal Shah – There are two major classifications of drug-receptor activity: agonism and antagonism. Agonism occurs when a molecule binds to a receptor, causes an exertion of normal receptor operation, and eventually causes a response. Antagonism of a receptor occurs when a molecule binds to the receptor and does not allow activity to occur.1… |
![]() |
Faculty Spotlight: Dr. Abu Serajuddin...
November 1, 2011 - Featured , Professional Advice / Opinions By: Ebey P. Soman – Dr. Abu Serajuddin is a true inspiration for student pharmacists who wish to enter the pharmaceutical industry setting. He attained his Bachelors of Pharmacy with honors at Dhaka University in Bangladesh and majored in Pharmaceutics to get his Master of Sciences degree at Columbia University in New York. He obtained… |